|
Video: What is a Stock Split?
|
|
Akari Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for acute and chronic inflammation, specifically through the inhibition of the complement (C5) and leukotriene pathways. Co.'s primary product candidate, nomacopan, inhibits both terminal C5 activation and leukotriene B4 (LTB4). Co.'s clinical targets for nomacopan are orphan inflammatory diseases where the inhibition of both C5 and LTB4 are implicated, including bullous pemphigoid, pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy, and as well as inflammatory conditions in the eye and lung including dry eye, dry AMD and COVID-19 pneumonia. According to our Akari Therapeutics PLC stock split history records, Akari Therapeutics PLC has had 1 split. | |
|
Akari Therapeutics PLC (AKTX) has 1 split in our Akari Therapeutics PLC stock split history database. The split for AKTX took place on August 17, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of AKTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Akari Therapeutics PLC conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Akari Therapeutics PLC stock split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Akari Therapeutics PLC shares, starting with a $10,000 purchase of AKTX, presented on a split-history-adjusted basis factoring in the complete Akari Therapeutics PLC stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/18/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$119.80 |
|
End price/share: |
$1.86 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.44% |
|
Average Annual Total Return: |
-34.89% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$155.64 |
|
Years: |
9.70 |
|
|
|
Date |
Ratio |
08/17/2023 | 1 for 20 |
|
|